• Login
  • Register
Nairametrics
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
Nairametrics
Home Sectors Health

Ranking: Malaria drugs in Nigeria based on prices as of November 2023 

Chioma Chukwunedu by Chioma Chukwunedu
November 27, 2023
in Health, Metrics, Rankings
Ekiti state introduces free malaria treatment, free delivery for pregnant women, others    
Share on FacebookShare on TwitterShare on Linkedin

According to the World Health Organization report on malaria, Nigeria has the highest burden of malaria globally, accounting for nearly 27% of the global malaria burden.  

The risk of malaria transmission exists all year round. Malaria is a major public health issue in Nigeria with an estimated 68 million cases and 194,000 deaths.

However, the incidence of malaria is highest in the northern and northeastern parts of the country.  

MoreStories

Top 10 African Countries with the highest lending rate as of October 2025 

Top 10 best-performing African currencies in February 2026

March 10, 2026
NGX

Top 10 Nigerian stockbrokers behind February 2026’s biggest trades

March 10, 2026

Despite the malaria epidemic, Nigeria loses N75.5 billion on each cycle of malaria treatment according to a leading biotechnology and genetic engineering professor.  

A breakdown of costs by Nairametrics showed that of the 68 million cases, an average Nigerian spends an average of 2000 naira for uncomplicated malaria totaling 136 billion naira annually: and spends an average of 20,000 naira for complicated malaria totaling 1.36 trillion naira annually.  

Nairametrics has ranked the most expensive antimalarial medicines available in Nigeria. 

  1. Camosunate adult 

Price range: N1500- N2100 

Camosunate Adult is a common anti-malaria brand which has a unique combination of Artesunate and Amodiaquine. It is used to treat uncomplicated malaria attacks including multi-drug resistance of Plasmodium falciparum. It is marketed by Geneith Pharmaceuticals Ltd.  

  1. Artequick tablets

Price range: N2000-N2100 

Artequick tablets are manufactured by a Chinese pharmaceutical company, Artepharm Co. Ltd. Artequick contains Artemisinin and Piperaquine. It is used to treat uncomplicated malaria. 

  1. P-alaxin tablets

Price range: N1300-N2500 

P-Alaxin tablets is manufactured by Indian pharmaceutical company, BLISS CVS PHARMA Ltd and marketed by Greenlife Pharmaceuticals, Nigeria. P-alaxin is an artemisinin-based therapy used to treat malaria.  

  1. Amatem forte soft gel

Price range: N2500-N3000 

Amatem softgel capsules are used for the treatment of Plasmodium falciparum malaria cases resistant to chloroquine and sulphadoxine and pyrimethamine combination. It is manufactured in India by Olive Healthcare and marketed by Elbe Pharma Nigeria Limited.  

  1. Lonart DS 

Price range: N2500-N3500 

Lonart DS tablets are used to treat malaria including multi-drug resistant strains of Plasmodium falciparum. It is manufactured by Indian Pharmaceuticals, BLISS GVS PHARMA Ltd and marketed in Nigeria by Greenlife Pharmaceuticals. 

  1. Coartem

Price range: N3500-N5000 

Coartem is a product of the Swiss-based pharmaceutical giant, Novartis. It is used to treat uncomplicated malaria.  

  1. Paludrine tablets

Price range: N2000 –N2500 per sachet. Patients may require up to 3 sachets or more. 

Paludrine belongs to the antimalarials and is used to prevent malaria. It is manufactured by a global company, Alliance Pharmaceuticals.  

  1. E mal injection 

Price range: N4000-N6000 

E mal injection is used to treat uncomplicated malaria. It is manufactured by Nigeria’s pharmaceutical company, Fidson Healthcare.  

  1. Artequin adult tablets

Price range: N10,000-N20,000 

Artequin tablets are manufactured by Switzerland-based pharmaceutical company, Acino. It is used to treat malaria which is resistant to other anti-malaria drugs. 

  1. Malanil

Price range: N50,000-N55,000 

Malanil tablets are fixed-dose combination medicines used to treat and prevent malaria, including chloroquine-resistant malaria. It is manufactured by British-based pharmaceutical giant, GlaxoSmithKline popularly known as GSK.  

 

 

 


Add Nairametrics on Google News
Follow us for Breaking News and Market Intelligence.
Tags: Fidson Healthcare Plc - NewsMalaria
Chioma Chukwunedu

Chioma Chukwunedu

Chioma Chukwunedu is a pharmacist and health analyst. She uses data and articles to educate the public about healthcare services and systems so they can make informed decisions about their health.

Next Post
Mr. Festus Keyamo,

FEC approves N3.2 billion for procurement of airport scanners 

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

rabafast
rabafast

nairametrics





DUNS

Follow us on social media:

  • HOME
  • ABOUT NAIRAMETRICS
  • CONTACT US
  • DISCLAIMER
  • ADs DISCLAIMER
  • COPYRIGHT INFRINGEMENT

© 2026 Nairametrics

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Social Media Auto Publish Powered By : XYZScripts.com
No Result
View All Result
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
  • Login
  • Sign Up

© 2026 Nairametrics